PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

PTC Therapeutics (NASDAQ: PTCT) announced inducement equity grants approved April 13, 2026 for a new non-executive employee under Nasdaq Listing Rule 5635(c)(4).

The company granted non-statutory stock options to purchase 1,155 shares and 925 RSUs. Options have a $70.42 exercise price, 10-year term, and four-year vesting schedules; RSUs vest over four years.

News Market Reaction – PTCT

-0.15%

-0.15% Session close to close

In the Apr 20 session, PTCT declined 0.15%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details a routine Nasdaq Rule 5635(c)(4) inducement grant to a single new non‑exec...

Analysis

This announcement details a routine Nasdaq Rule 5635(c)(4) inducement grant to a single new non‑executive employee: 1,155 options and 925 RSUs at an exercise price of $70.42, vesting over 4 years. It follows earlier equity-based compensation and governance updates that saw modestly positive reactions. Investors may contextualize this within ongoing insider equity activity and the company’s broader fundamentals, including prior disclosure of $1.731B 2025 revenue and significant cash reserves.

Key Figures

Current price: $72.43 Stock options granted: 1,155 shares RSUs granted: 925 RSUs +5 more

8 metrics

Current price $72.43 Pre-news trading level on publication date

Stock options granted 1,155 shares Non-statutory stock options to new non-executive employee

RSUs granted 925 RSUs Restricted stock units to new non-executive employee

Option exercise price $70.42 per share Closing price on grant date April 13, 2026

Option term 10 years Duration of non-statutory stock options

Initial vesting tranche 25% Options and RSUs vesting on first anniversary/new hire anniversaries

Quarterly vesting rate 6.25% Ongoing quarterly vesting for option grants after year one

Vesting period 4 years Total vesting duration for options and RSUs

Historical Context

5 past events · Latest: Mar 25 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 25	Board appointment	Positive	+3.4%	Industry veteran added to board to support next stage of growth.
Mar 13	Inducement grants	Neutral	+2.5%	Equity awards to 18 new employees under Nasdaq inducement rules.
Feb 23	Investor conferences	Neutral	-0.2%	Announcement of three early March investor conference presentations.
Feb 19	Earnings update	Positive	+1.1%	Reported 2025 revenues of $1.731B and strong cash balance of $1.945B.
Feb 18	Industry outlook	Positive	+1.4%	PKU market forecast to grow driven by diagnosis and innovative therapies.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent company-specific announcements, including governance, inducement grants, and earnings, have more often been followed by modest positive price reactions than by declines.

Recent Company History

Over the last few months, PTC has reported multiple corporate developments. A board appointment on Mar 25, 2026 and prior inducement grants on Mar 10, 2026 both coincided with positive moves. Earnings on Feb 19, 2026 highlighted $1.731B in 2025 revenue and $1.945B year-end cash, with a constructive price reaction. Conference participation and broader PKU market commentary had smaller effects. Today’s single-employee inducement grant fits into a pattern of routine equity-based compensation disclosures.

Key Terms

non-statutory stock options, restricted stock units, nasdaq inducement grant exception, nasdaq listing rule 5635(c)(4)

4 terms

non-statutory stock options financial

"approved non-statutory stock options to purchase an aggregate of 1,155 shares"

Non-statutory stock options are a type of reward that companies give to employees, allowing them to buy company shares at a set price within a certain period. Unlike formal or government-approved plans, these options are more flexible but may have different tax implications. For investors, they can influence a company's stock price and financial health, making them an important factor to consider.

restricted stock units financial

"and 925 restricted stock units ("RSUs"), each representing the right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq inducement grant exception regulatory

"The awards were made pursuant to the Nasdaq inducement grant exception as a component"

A Nasdaq inducement grant exception is a narrow rule that lets a listed company give stock or options to a newly hired employee without first getting shareholder approval, provided the award meets strict size, timing and disclosure conditions. For investors it matters because such grants can dilute existing shares, signal how the company attracts talent, and affect executive incentives—similar to a signing bonus paid partly in stock instead of cash.

nasdaq listing rule 5635(c)(4) regulatory

"with the company in accordance with Nasdaq Listing Rule 5635(c)(4).All stock option awards"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WARREN, N.J., April 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 13, 2026, the company approved non-statutory stock options to purchase an aggregate of 1,155 shares of its common stock and 925 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to a new non-executive employee. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hire's employment compensation.

The inducement grant was approved by PTC's Compensation Committee on April 13, 2026, and is being made as an inducement material to the employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

All stock option awards have an exercise price of $70.42 per share, the closing price of PTC's common stock on April 13, 2026, the date of the grant. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the company through the vesting dates. The RSUs each will vest over four years, with 25% of the original number of shares vesting on each annual anniversary of the employee's new hire date until fully vested, subject to the employee's continued service with the company through the vesting dates.

ABOUT PTC THERAPEUTICS, INC.
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow us on LinkedIn, X, Instagram and Facebook.

For more information, please contact:

Investors:
Ellen Cavaleri
+1 (615) 618-8228
ecavaleri@ptcbio.com

Media:
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302744354.html

SOURCE PTC Therapeutics, Inc.

FAQ

What equity did PTC Therapeutics (PTCT) grant on April 13, 2026?

PTC Therapeutics granted non-statutory options for 1,155 shares and 925 RSUs to a new non-executive employee. According to the company, the awards were approved April 13, 2026 under the Nasdaq inducement exception, as part of the hire package.

What is the exercise price and term for PTCT stock options granted April 13, 2026?

The exercise price for the options is $70.42 per share and each option has a 10-year term. According to the company, $70.42 was the closing price on April 13, 2026, the grant date.

How do the PTCT granted options vest for the new hire?

The options vest over four years: 25% at first anniversary then 6.25% every three months thereafter until fully vested. According to the company, vesting is subject to the employee's continued service through each vesting date.

What is the vesting schedule for the PTCT RSUs granted April 13, 2026?

The RSUs vest over four years with 25% vesting on each annual anniversary of the hire date until fully vested. According to the company, vesting is contingent on the employee's continued service through each anniversary.

Why were these inducement grants made under Nasdaq Listing Rule 5635(c)(4) by PTCT?

The grants were made as an inducement material to the employee's acceptance of employment under Nasdaq Rule 5635(c)(4). According to the company, the awards were approved by the compensation committee on April 13, 2026.